Compare Newmont Corporation (NEM) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Newmont Corporation vs Novartis AG — how do they compare? Newmont Corporation trades at $117.51 (market cap $121.75B), while Novartis AG trades at $143.49 (market cap $268.57B). The key difference: Novartis AG is far larger — about 2.2× Newmont Corporation's market cap, and Novartis AG pays the higher dividend (3.31%). Which is the better fit depends on your goals — on Pluang, investors hold Newmont Corporation for 58 Days and Novartis AG for 82 Days on average.
| NEM | NVS | |
|---|---|---|
Market Cap | $121.75B | $268.57B |
Volume | 5,421,125 | 1,532,573 |
Sector | Basic Materials | Health |
52-Week High | $135.14 | $168.62 |
52-Week Low | $78.63 | $121.80 |
Typical Hold Time | 58 Days | 82 Days |
Enterprise Value | $118.34B | $309.89B |
Dividend Yield | 0.9% | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Newmont Corporation (NEM) trades at $113.54, down 2.45% over 24 hours, with technical indicators showing a bearish short-term trend. The company reported strong fundamentals, including record free cash flow of $5.3 billion in H1 2026 (Defense World, 2026-10-01) and consistent earnings beats in recent quarters. Revenue grew to $22.67 billion in 2025, with net income margin improving to 31.25%. Analyst sentiment remains positive, with a consensus price target of $136.83 and 76% buy ratings.
The outlook for NEM is supported by robust cash flow generation and operational improvements, but near-term price pressure exists from technical bearish signals and gold price volatility. Investment appeal lies in its valuation metrics, such as a P/E of 14.57, and shareholder returns via dividends. Key risks include sensitivity to gold prices and execution of growth projects. The stock offers value for long-term investors despite current market weakness.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Newmont Corporation
Newmont Corp is primarily a gold producer with operations and/or assets in the United States, Canada, Mexico, Dominican Republic, Peru, Suriname, Argentina, Chile, Australia, and Ghana. It is also engaged in the production of copper, silver, lead and zinc. The company's operations are organized in five geographic regions: North America, South America, Australia, Africa and Nevada.
Read more on NEM →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
